deaths (OS)progression or deaths (PFS)RFS/DFS

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus trastuzumab plus capecitabine
tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine 2 certainty unassessablestatistically conclusive-31% certainty unassessablestatistically conclusive-42%-